Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development.
The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III trial of the treatment is under way.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical names VP business development | Personnel Moves, Nov. 8, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/2ejm74y
Cap comentari:
Publica un comentari a l'entrada